Project Details
Abstract
Parkinson’s disease (PD) affects ~ 1 % of the population above the age of 60 and is the most
common neurodegenerative motor disorder. The majority (~90 %) of PD cases is sporadic, and
Mendelian familial forms of Parkinson’s disease accountfor ~10 % of PD patients. Up to now, the exact
molecular mechanisms underlying the degeneration of dopaminergic neurons in substantia nigra pars
compacta (SNpc) and molecular pathogenesis of PD is not completely understood. Identification of
genes linked to familiar forms of PD led to a better understanding of novel proteins and molecular
pathways that may cause the neurodegeneration of SNpc dopaminergic cells and resulting parkinsonism.
Patients with familial type 8 of Parkinson’s disease (PARK8) exhibit late-onset parkinsonism symptoms
and autosomal dominant inheritance. Molecular genetic studies identified missense mutations of
leucine-rich repeat kinase 2 (LRRK2) as the cause of PARK8. LRRK2 mutation is the most common
genetic cause of both familial and sporadic PD cases. Mutations of PTEN-induced kinase 1 (PINK1)
gene cause recessive familial type 6 of Parkinson’s disease(PARK6). PINK1 is the second most
frequent causative gene in early-onset PD, and PINK1 mutations are also found in sporadic PD patients.
Clinical features of PARK8 or PARK6 patients are similar to those of sporadic PD patients, suggesting
that common molecular pathogenic mechanisms cause PARK8, PARK6 and sporadic PD. Thus, a better
understanding of cellular and molecular mechanisms underlying mutant LRRK2- or PINK1-induced
parkinsonism is expected to unravel the pathogenic mechanism of PARK8, PARK6 and sporadic PD.
In order to investigate molecular pathogenic mechanisms of PD and develop therapeutic strategy and
biomarker of PD, our Integrated Research Project consists of the following three sub-projects: (1)
Sub-project 1: Investigating molecular pathogenic mechanisms of PARK8 using knockin mouse model.
(2) Sub-project 2: Investigating molecular pathogenic mechanisms of PARK6 using knockin mouse
model. (3) Sub-project 3: From mouse models to patients: Development of a novel 18F-DTBZ PET
imaging as a biomarker to monitor neurodegeneration of PARK6 and PARK8 parkinsonism. Specific
aims of our Integrated Research Project include: (1) To investigate molecular pathogenic mechanisms of
PARK6, PARK8 and sporadic PD using PARK6 and PARK8 knockin mouse models. (2) To test possible
therapeutic effect of small-molecule LRRK2 inhibitors using PARK8 knockin mouse models. (3) To
evaluate 18F-DTBZ PET imaging as a biomarker for disease progression of PARK6, PARK8 and
idiopathic PD patients. Long-term objectives of our Integrated Research Project are: (A) PARK6 or
PARK8 knockin mice are used to establish a standard and stable animal platform for developing new PD
drugs. (B) Discovering new drug or therapeutic strategy of PD for further clinical application.
Among LRRK2 mutations found in PARK8 and sporadic PD patients, G2019S and Y1699C are two
of the most prevalent mutations. In this sub-project 1 of our Integrated Research Project, animal model
of mutant (G2019S) or (Y1699C) LRRK2-induced PD is prepared by generating humanized knockin
mice expressing PARK8 mutant (G2019S) or (Y1699C) LRRK2. Then, we will investigate molecular
pathogenic mechanisms of (Y1699C) or (G2019S) LRRK2-induced parkinsonism by performing the
following experiments using LRRK2Y1699C/+or LRRK2G2019S/+ knockin mice, which display PD
neuropathological phenotypes and motor deficits: (1) We will study molecular mechanisms underlying
mutant (G2019S) or (Y1699C) LRRK2-induced degeneration of SNpc dopaminergic neurons in
LRRK2Y1699C/+or LRRK2G2019S/+ knockin mice. (2) We will test the possibility that mutant (Y1699C) or
(G2019S) LRRK2 causes the dysfunction of SNpc dopaminergic or striatal medium spiny neurons of
LRRK2Y1699C/+or LRRK2G2019S/+ knockin mice, leading to an impaired motor function of nigrostriatal
dopaminergic pathway and parkinsonism. (3) Quantitative phosphoproteomic analysis is performed to
identify putative substrates of mutant (Y1699C) or (G2019S) LRRK2 in the brain of LRRK2Y1699C/+or
LRRK2G2019S/+ knockin mice. (4)We will test possible therapeutic effect of small-molecule LRRK2
kinase inhibitors on PD neurological phenotypes of LRRK2Y1699C/+ or LRRK2G2019S/+ knockin mice.
Project IDs
Project ID:PC10009-0045
External Project ID:NSC100-2321-B182-008
External Project ID:NSC100-2321-B182-008
Status | Finished |
---|---|
Effective start/end date | 01/08/11 → 31/07/12 |
Keywords
- Parkinson’s disease
- Familial type 8 of Parkinson’s disease (PARK8)
- Leucine-rich repeat kinase 2
- Substantia nigra dopaminergic neurons
- PARK8 knockin mouse
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.